Recent Analysts’ Ratings Changes for Liquidia (LQDA)

A number of research firms have changed their ratings and price targets for Liquidia (NASDAQ: LQDA):

• 1/13/2026 – Liquidia had its price target raised by analysts at Jefferies Financial Group Inc. from $45.00 to $55.00. They now have a “buy” rating on the stock.
• 1/13/2026 – Liquidia had its price target raised by analysts at Jefferies Financial Group Inc. from $45.00 to $55.00. They now have a “buy” rating on the stock.
• 1/13/2026 – Liquidia was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 1/10/2026 – Liquidia was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/9/2026 – Liquidia had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock.
• 12/26/2025 – Liquidia had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock.
• 12/6/2025 – Liquidia was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Insider Buying and Selling

In other Liquidia news, insider Scott Moomaw sold 20,533 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $768,550.19. Following the completion of the sale, the insider directly owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. The trade was a 11.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the transaction, the general counsel directly owned 579,394 shares in the company, valued at approximately $21,686,717.42. This trade represents a 4.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 323,354 shares of company stock worth $11,046,731. 26.50% of the stock is currently owned by corporate insiders.

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).